1,55 $
1,27 % gestern
NYSE, 3. Oktober, 22:19 Uhr
ISIN
US35168W1036
Symbol
GUTS
Berichte

Fractyl Health Aktie News

Positiv
Seeking Alpha
3 Tage alt
Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 million market cap, given de-risked Revita data and a robust cash position following recent financings. Revita's unique, durable weight loss profile and minimal side effects position it as a one-tim...
Neutral
Seeking Alpha
8 Tage alt
Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Jason Gerberry - BofA Securities, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division William ...
Positiv
Reuters
8 Tage alt
Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.
Neutral
GlobeNewsWire
8 Tage alt
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offer...
Neutral
GlobeNewsWire
8 Tage alt
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients
Positiv
Seeking Alpha
29 Tage alt
Fractyl Health's Revita offers a one-time procedure to maintain GLP-1 weight loss, with pivotal 45-patient trial data expected imminently. Early open-label results show Revita may significantly reduce post-GLP-1 weight regain. Despite past "OK" results in T2D, Revita's may have found its killer application in GLP-1 discontinuation patient; awarded FDA Breakthrough Device Designation.
Neutral
GlobeNewsWire
etwa ein Monat alt
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors
Neutral
Seeking Alpha
etwa 2 Monate alt
Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian Luque - Corporate Participant Harith Rajagopalan - Co-Founder, CEO & Director Lisa A. Davidson - CFO & Treasurer Conference Call Participants Jason Matthew Gerberry - BofA Securities, Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division W...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen